<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04867720</url>
  </required_header>
  <id_info>
    <org_study_id>B95_03LT2001</org_study_id>
    <nct_id>NCT04867720</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of CertiroBell速 Tablet Plus Tacrolimus in Primary Living Donor Liver Transplant Recipients</brief_title>
  <acronym>STELLA</acronym>
  <official_title>Multi-center, Single Arm, Open-label, Phase 4 STudy to Evaluate the Efficacy and Safety of CertiroBELL速 Tablet Plus TAcrolimus in Primary Living Donor Liver Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of CertiroBell速 tablet plus tacrolimus&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is multi-center, single arm, open-label, phase 4 study to evaluate the efficacy&#xD;
      and safety of CertiroBell速 tablet plus tacrolimus in primary living donor liver transplant&#xD;
      recipients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2021</start_date>
  <completion_date type="Anticipated">February 22, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 10, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of composite efficacy failure</measure>
    <time_frame>until 24 weeks after taking medicine</time_frame>
    <description>composite efficacy failure include biopsy-confirmed acute rejection, graft loss, death, or follow-up failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of biopsy-confirmed acute rejection</measure>
    <time_frame>until 24 weeks after taking medicine</time_frame>
    <description>acute rejection confirmed by result of biopsy(over 4 points of RAI score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological result, time of occurrence, treatment method and treatment result of acute rejection confirmed by biopsy(over 4 points of RAI score)</measure>
    <time_frame>until 24 weeks after taking medicine</time_frame>
    <description>details of acute rejection confiremd by result of biopsy(over 4 points of RAI score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival rate of patients</measure>
    <time_frame>until 24 weeks after taking medicine</time_frame>
    <description>Survival rate of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival rate of transplanted organ</measure>
    <time_frame>until 24 weeks after taking medicine</time_frame>
    <description>Survival rate of transplanted organ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of liver cancer</measure>
    <time_frame>until 24 weeks after taking medicine</time_frame>
    <description>Incidence rate of liver cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate of liver cancer</measure>
    <time_frame>until 24 weeks after taking medicine</time_frame>
    <description>Recurrence rate of liver cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of CMV infection</measure>
    <time_frame>until 24 weeks after taking medicine</time_frame>
    <description>Incidence rate of CMV infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of serum creatinine, eGFR(estimated glomerular filtration rate) compared to baseline using MDRD(Modification of Diet in Renal Disease)</measure>
    <time_frame>until 24 weeks after taking medicine</time_frame>
    <description>eGRF using MDRD(Modification of Diet in Renal Disease) method</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Liver Transplant</condition>
  <arm_group>
    <arm_group_label>CertiroBell Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use in combination with Tacrolimus at least 6 months after liver transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>- Oral intake, BID - After first dose 1mg(total 2mg daily), check the blood concentration of everolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3~8mg/mL.</description>
    <arm_group_label>CertiroBell Tablet</arm_group_label>
    <other_name>CertiroBell Tab.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who had liver transplantation from living donor and had passed over 3 months&#xD;
             since operation.&#xD;
&#xD;
          2. Over 20 years old&#xD;
&#xD;
          3. Patients who are being treated with Tacrolimus at screening visit&#xD;
&#xD;
          4. Patients who agreed to written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who had received non-liver organs before liver transplantation or had&#xD;
             received other organs while receiving liver.&#xD;
&#xD;
          2. Patients who had auxiliary partial orthotopic liver transplantation or had&#xD;
             bioartifical liver&#xD;
&#xD;
          3. Patients who have been diagnosed with acute rejection within 6 months and have been&#xD;
             treated&#xD;
&#xD;
          4. Patients who had hepatic artery complication such as hepatic artery thrombosis within&#xD;
             recent 6 months&#xD;
&#xD;
          5. Patients who have been diagnosed with malignant tumor within 5 years(however, the&#xD;
             following will be excepted)&#xD;
&#xD;
               -  fully recovered from skin cancer(squamous cell/basal cell carcinoma or thyroid&#xD;
                  cancer)&#xD;
&#xD;
               -  haptocellular carcinoma without main vessel invasion&#xD;
&#xD;
          6. Patients with severe systemic infection&#xD;
&#xD;
          7. Patients who are difficult to communicate due to mental disorder&#xD;
&#xD;
          8. Patients who are in treatment for hapatitis, or are over 3 times higher than upper&#xD;
             normal limit in liver function test(T-bilirubin, AST, ALT) or over 5 times higher than&#xD;
             normal limit of ALP&#xD;
&#xD;
          9. Patients who are(at screening visit)&#xD;
&#xD;
               -  WBC&lt;1,500/mm^3&#xD;
&#xD;
               -  PLT&lt;30,000/mm^3&#xD;
&#xD;
               -  over 1.0 in Protein/creatinine ratio(UA test)&#xD;
&#xD;
               -  eGFR&lt;30mL/min/1.73m^2(MDRD)&#xD;
&#xD;
               -  Total Cholesterol&gt;350mg/dL or Triglycerides&gt;500mg/dL&#xD;
&#xD;
         10. Patients taking HCV(hapatitis C virus) therapeutic drug or anti-HCV positive patients&#xD;
             who have positive result in HCV RNA test at screening visit&#xD;
&#xD;
         11. Patients who had plasmapheresis within 1 week&#xD;
&#xD;
         12. Those who are pregnant, nursing, or are not practicing contraception with appropriate&#xD;
             method&#xD;
&#xD;
         13. Patients who had plasmapheresis within 3 months&#xD;
&#xD;
         14. if participated in other trail within 4 weeks(28 days)&#xD;
&#xD;
         15. In investigator's judgement&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Suk Suh, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kyung-Suk Suh, M.D., Ph.D.</last_name>
    <phone>82-2-2072-7200</phone>
    <email>kssuh@snu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hosipital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyung-Suk Suh, M.D.,Ph.D.</last_name>
      <phone>82-2-2072 7200</phone>
      <email>kssuh@snu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>April 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2021</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Everolimus</keyword>
  <keyword>CertiroBell</keyword>
  <keyword>Tacrolimus</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

